INOVIO (NASDAQ: INO) released its financial results and operational highlights for 2024, marking significant strides in its ...
5don MSN
Q4 2024 Management View CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary focus on advancing INO-3107, a DNA medicine for ...
Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback